<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A bispecific ligand-directed toxin (BLT) called DT2219ARL consisting of two scFv ligands recognizing CD19 and CD22 and catalytic DT390 was genetically enhanced for superior in vivo anti-<z:hpo ids='HP_0001909'>leukemia</z:hpo> activity </plain></SENT>
<SENT sid="1" pm="."><plain>Genetic alterations included reverse orienting VH-VL domains and adding aggregation reducing/stabilizing linkers </plain></SENT>
<SENT sid="2" pm="."><plain>In vivo, these improvements resulted in previously unseen long-term <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-free survivors measured in a bioluminescent xenograft imaging model in which the progression of human Raji Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> could be tracked in real time and in a Daudi model as well </plain></SENT>
<SENT sid="3" pm="."><plain>Studies showed DT2219ARL was potent (IC50s 0.06-0.2 nM range) and selectively blockable </plain></SENT>
<SENT sid="4" pm="."><plain>Imaging studies indicated the highly invasive nature of this B cell <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> model and showed it likely induced pre-terminal hind limb <z:hpo ids='HP_0003470'>paralysis</z:hpo> because of <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> to spinal regions prevented by DT2219ARL </plain></SENT>
<SENT sid="5" pm="."><plain>DT2219ARL represents a new class of bispecific biological that can be continually improved by genetic mutation </plain></SENT>
</text></document>